Table 5.
TEAEs occurring in ≥2 patients in any treatment group (safety population)
| TEAE, n (%) | Number of patients (%) reporting TEAE | ||||||
|---|---|---|---|---|---|---|---|
| Placebo (N = 68) | Indacaterol 150 μg (N = 68) | Abediterol | Total (N = 70) | ||||
| 0.625 μg (N = 67) | 2.5 μg (N = 66) | 5 μg (N = 66) | 10 μg (N = 67) | ||||
| Any | 9 (13.2) | 10 (14.7) | 7 (10.4) | 5 (7.6) | 6 (9.1) | 9 (13.4) | 32 (45.7) |
| Nasopharyngitis | 2 (2.9) | 5 (7.4) | 4 (6.0) | 1 (1.5) | 1 (1.5) | 2 (3.0) | 15 (21.4) |
| Headache | 3 (4.4) | 0 | 1 (1.5) | 0 | 2 (3.0) | 2 (3.0) | 8 (11.4) |
| Dyspnoea | 0 | 2 (2.9) | 0 | 0 | 0 | 0 | 2 (2.9) |
TEAE treatment-emergent adverse event